- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kazia Therapeutics Ltd ADR (KZIA)
The Kazia Therapeutics ADR share price today is 9.4900, view NASDAQ KZIA stock exchange data. Track the latest Kazia Therapeutics ADR share price with real-time updates on KZIA stock performance including market cap, day range, 52-week range and dividend yield. Access KZIA charts, earnings dates and analyst estimates to support your investment decisions.
NASDAQ
Currency in USD
9.4900
-0.2900(-2.97%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.4200
9.9899
52 wk Range
4.8600
17.4000
KZIA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.42009.9899
52 wk Range
4.860017.4000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KZIA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
28.4978
Upside
+200.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 28.4978
(+200.29% Upside)
Earnings
Latest Release
07-11-2025
EPS / Forecast
-7.64 / -221.00
Revenue / Forecast
1.81M / --
Compare KZIA to Peers and Sector
Metrics to compare | KZIA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKZIAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.2x | 11.2x | −0.4x | |
PEG Ratio | −0.11 | 0.33 | 0.00 | |
Price/Book | 4.0x | 1.3x | 2.6x | |
Price / LTM Sales | 98.8x | 1.6x | 3.0x | |
Upside (Analyst Target) | 191.8% | 616.5% | 57.0% | |
Fair Value Upside | Unlock | 2.0% | 8.0% | Unlock |
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Kazia Therapeutics ADR (KZIA) Share Price Today?
The Kazia Therapeutics ADR share price today is 9.4900.
What is the current Kazia Therapeutics ADR (KZIA) share price and day range?
As of 25-09-2026, the Kazia Therapeutics ADR share price is 9.4900, with a previous close of 9.7800. The share price has ranged from 9.4200 to 9.9899 today, while the 52-week range spans from 4.8600 to 17.4000.
What Is the Kazia Therapeutics ADR Market Cap?
As of today, Kazia Therapeutics ADR market cap is 134.0200M.
What Is the Kazia Therapeutics ADR (KZIA) Share Price Target?
The average 12-month share price target for Kazia Therapeutics ADR is 28.4978, with a high estimate of 39.41589651 and a low estimate of 17.57908555. 6 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +200.29% Upside potential.
What Is Kazia Therapeutics ADR's Earnings Per Share (TTM)?
The Kazia Therapeutics ADR EPS (TTM) is -10.2231.
From a Technical Analysis Perspective, Is KZIA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Kazia Therapeutics ADR Trade On?
Kazia Therapeutics ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Kazia Therapeutics ADR?
The stock symbol for Kazia Therapeutics ADR is "KZIA."
How Many Times Has Kazia Therapeutics ADR Stock Split?
Kazia Therapeutics ADR has split 4 times.
How Many Employees Does Kazia Therapeutics ADR Have?
Kazia Therapeutics ADR has 6 employees.
What Is the KZIA Premarket Price?
KZIA's last pre-market stock price is 9.8000. The pre-market share volume is 310.0000, and the stock has changed by 0.0200, or 0.2000%.
What Is the KZIA After Hours Price?
KZIA's last after hours stock price is 10.0000, the stock has changed by 0.2200, or 2.2500%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.